Post-Patent GLP-1s: A Win for Access or a Blow to Safety?



Over a dozen phase 3 trials for generic semaglutide are underway in China, setting the stage for one of the world’s largest generic launches.
Medscape Medical News



Source link : https://www.medscape.com/viewarticle/post-patent-glp-1s-win-access-or-blow-safety-2025a1000ron?src=rss

Author :

Publish date : 2025-10-14 13:02:00

Copyright for syndicated content belongs to the linked Source.
Exit mobile version